Who founded ParcelBio?

ParcelBio was founded by David Weinberg, Chris Carlson in 2023.

Who are ParcelBio's investors?

ParcelBio's investors include Y Combinator, Breyer Capital, General Catalyst, Alumni Ventures, Lexi Ventures, Metaplanet, North South Ventures, Pioneer and 11 more.

How much funding has ParcelBio raised?

ParcelBio has disclosed $13.2M raised across 1 round.

Where is ParcelBio headquartered?

ParcelBio is headquartered in San Francisco, US.

ParcelBio

YC W24

San Francisco, US · Founded 2023 · Delaware corporation · 6 employees · 20 known investors

Find your way into ParcelBio

Paths you didn't know you had: your email and LinkedIn already hold routes to the ParcelBio team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.

Also known as Parcel Biosciences, Inc. · Parcel Therapeutics · Parcel Therapuetics · Parcel Therapuetics, Parcel Therapeutics

AI & Machine Learning Biotech Deep Tech Healthtech Gene Therapy Synthetic Biology Therapeutics Drug discoveryUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W24)

ParcelBio was founded in 2023 by David Weinberg and Chris Carlson.

David Weinberg Co-Founder and CEOHe previously held VP-level roles at Orbital Therapeutics/Circ Bio leading RNA platform development and at Freenome as Sr. Director of Molecular Research building multiomics diagnostics capabilities. He holds a PhD from MIT and was a UCSF Faculty Fellow.

Chris Carlson Co-Founder and CSOHe previously worked as a scientist at Orbital Therapeutics, where he contributed to patents on RNA stabilization, and holds a PhD in RNA virology from UCSF.

Board

Morgan Cheatham Board directorPartner and Head of Healthcare and Life Sciences at Breyer Capital

Investors · 20

Y Combinator✓ confirmed by ParcelBioSan Francisco · $500K

How we know: the Y Combinator directory · funding news · technews180.com · open dataset · 5k.vc investor directory · Not right? Tell us

Breyer Capital✓ confirmed by ParcelBioAustin · $500K – $10M

How we know: the company's own site · funding news · technews180.com · Y Combinator's founder network · Not right? Tell us

General Catalyst✓ confirmed by ParcelBioSan Francisco · $30M

How we know: the company's own site · funding news · technews180.com · Y Combinator's founder network · Not right? Tell us

Alumni Ventureslisted by Alumni VenturesManchester · $100K – $10M

How we know: Y Combinator's founder network · av.vc · Not right? Tell us

Lexi Ventureslisted by Lexi VenturesSan Francisco

How we know: Lexi Ventures's portfolio page · Not right? Tell us

Metaplanetlisted by MetaplanetTallinn · $500K – $10M

How we know: Metaplanet's portfolio page · technews180.com · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

North South Ventureslisted by North South VenturesToronto

How we know: Y Combinator's founder network · Not right? Tell us

Pioneerlisted by PioneerToronto, Ontario

How we know: Y Combinator's founder network · pioneerfund.vc · open dataset · 5k.vc investor directory · Not right? Tell us

Ritual Capitallisted by Ritual CapitalMenlo Park · $100K – $500Kvia Chris Howard · inferred

How we know: funding news · Y Combinator's founder network · Not right? Tell us

Spacecadet Ventureslisted by Spacecadet VenturesKent County · $100K – $500K

How we know: the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

SurgePoint Angellisted by SurgePoint AngelNew York

How we know: Y Combinator's founder network · Not right? Tell us

ZAKA VClisted by ZAKA VCSan Francisco

How we know: technews180.com · Y Combinator's founder network · Not right? Tell us

468 CapitalreportedBerlin

How we know: the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Attack CapitalreportedBrooklyn · $150K

How we know: Y Combinator's founder network · Not right? Tell us

BOND STreported

How we know: Y Combinator's founder network · Not right? Tell us

General Advancereported

How we know: Y Combinator's founder network · Not right? Tell us

Reinforced VenturesreportedPittsburgh

How we know: Y Combinator's founder network · Not right? Tell us

SBXireportedCambridge · $10K – $1M

How we know: Y Combinator's founder network · Not right? Tell us

Y InnovationsreportedCambridge

How we know: Y Combinator's founder network · Not right? Tell us

Also in the syndicate · 1

SurgePoint Capital

Reported raises · per SEC filings

Form D private placements

$13.2M disclosed across 1 round · 2026

▶$13.2MraisedMar 2026 · 52 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Morgan CheathamDirector
Christopher CarlsonExecutive Officer, Director
David WeinbergExecutive Officer, Director

Offering amount: $13.2M
Amount sold: $13.2M
First sale: Feb 2026
Incorporated: Corporation, Delaware, 2024
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 10

Kopra BioKopra Bio develops cancer immunotherapy technology that converts cancer cells into biofactories to produce their own destruction. The company operates in the biotech and cancer treatment space.

Modulari-TModulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.

Eclipse BioEclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.

Andson BiotechAndson Biotech develops analytical tools for the analysis of biotherapeutics, aimed at supporting the discovery and development of biologic drugs.

Senti BiosciencesSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.

FinalDoseFinalDose develops a programmable DNA-targeting molecule designed to recognize and destroy cells carrying specific genetic sequences, with initial applications in oncology across cancer types.

Dispatch BiotherapeuticsDispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.

Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.

Splice BioSpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes. The company is currently in clinical stages, with its lead program targeting Stargardt Disease.

Precision BioSciencesPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

Companies working in the same space as ParcelBio.

Legal entities · 1

corporate structure

Parcel Biosciences, Inc.

In the news

ParcelBio Raises $13M in Seed Fundingfinsmes.com · May 2026

Frequently asked questions

What does ParcelBio do?: ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.
Who founded ParcelBio?: ParcelBio was founded by David Weinberg, Chris Carlson in 2023.
Who are ParcelBio's investors?: ParcelBio's investors include Y Combinator, Breyer Capital, General Catalyst, Alumni Ventures, Lexi Ventures, Metaplanet, North South Ventures, Pioneer and 11 more.
How much funding has ParcelBio raised?: ParcelBio has disclosed $13.2M raised across 1 round.
Where is ParcelBio headquartered?: ParcelBio is headquartered in San Francisco, US.